drugset / Trial / NCT06599775
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
NaSingle-groupOpen-labelTreatment
Summary
Evaluating the efficacy and safety of PD-L1 (Programmed Death-L1)antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 (clinical stage tumor 1b-2) esophageal squamous cell carcinoma
Timeline
- Start
- 2024-10
- Primary completion
- 2026-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Albumin-Bound Paclitaxel | Unknown | — | — |
| Subject | Carboplatin | Small molecule | — | — |